Evidence map›Paper›PMID 40731127›Full record

ArticleScientific reports2025

Cytogenetic landscape aberrations in paediatric acute lymphoblastic leukaemia - a polish paediatric population treated according to ALL-IC BFM 2009 protocol.

Monika Lejman, Borys Styka, Joanna Zawitkowska, Anna Pastwińska, Ewa Studniak, Katarzyna Skonieczka, Marta Zacharczuk, Katarzyna Całka, Olga Haus, Panasiuk Barbara and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Monika LejmanIndependent Laboratory of Genetic Diagnostics, Medical University of Lublin, ul. Antoniego Gębali 6, Lublin, 20- 093, Poland. monika.lejman@umlub.pl.ORCID http://orcid.org/0000-0002-8760-0775
Borys StykaIndependent Laboratory of Genetic Diagnostics, Medical University of Lublin, ul. Antoniego Gębali 6, Lublin, 20- 093, Poland.
Joanna ZawitkowskaDepartment of Pediatric Haematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland.
Anna PastwińskaDepartment of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland.
Ewa StudniakCytogenetic Unit, Independent Public Clinical Hospital nr 2, Pomeranian Medical University, Szczecin, Poland.
Katarzyna SkonieczkaDepartment of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
Marta ZacharczukDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, Wrocław, Poland.
Katarzyna CałkaDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, Wrocław, Poland.
Olga HausDepartment of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
Panasiuk BarbaraDepartment of Clinical Genetics, Medical University of Bialystok, Białystok, Poland.
Beata SadowskaDepartment of Pediatric Oncology and Hematology, Cytogenetics and Molecular Genetics Laboratory, University Children's Hospital, Krakow, Poland.
Anna Przybyłowicz-ChaleckaDepartment of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Małgorzata Jarmuż-SzymczakInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Maria MalmInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Bartłomiej DropInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Jerzy R KowalczykDepartment of Pediatric Haematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic findings are important independent prognostic factors in childhood acute lymphoblastic leukaemia (ALL). This study presents cytogenetic data correlated with clinical factors of 1337 patients aged 1-18 years with newly diagnosed ALL treated between 2011 and 2018 under the Polish ALL IC-BFM 2009 therapeutic protocol. Overall survival (OS) for children with B-cell ALL was 95.58% at 5 years, while OS for children with T-cell ALL was 80.43% (p < 0.001). The event-free survival (EFS) rates were 86.69% and 72.92%, respectively, and the difference was also statistically significant (p < 0.001). The most common karyotypes observed were normal in 31.79% (n = 425) and high hyperdiploidy (HeH) in 18.4% (n = 246). Two aberrations were associated with a good prognosis in patients with B-cell ALL: ETV6::RUNX1 (OS = 98.47% and EFS 92.75%) and high hyperdiploidy (OS = 97.52% and EFS = 92.5%). Patients with low hyperdiploidy as well as patients with BCR::ABL1 aberration (OS = 73.05%, EFS = 73.05%) indicated a trend towards worse results (OS = 92.29%, EFS = 81.21%). Death and relapse rates were significantly higher in HeH patients without trisomy 17 and 18 compared to those with double trisomy 17 and 18 (p = 0.013). Our study advocates, cytogenetic testing remains an important tool in the diagnosis of paediatric patients with ALL IC-BFM 2009 protocol, as well as it shows that cytogenetic testing's use for treatment stratification improved the outcome of children with ALL in Polish paediatric onco-haematology centres.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChromosome AberrationsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolCytogenetic AnalysisFemaleHumansInfantMalePolandPrognosisBCR:ABL1Childhood acute lymphoblastic leukaemiaCytogenetics aberrationsETV6:RUNX1KaryotypeKMT2A-r

Identifiers

PMID40731127
PMCPMC12307753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.